Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 346Neoplasms 247Prostatic Neoplasms 198Colorectal Neoplasms 151Lung Neoplasms 130Carcinoma, Non-Small-Cell Lung 108Leukemia, Myeloid, Acute 107Pancreatic Neoplasms 98Multiple Myeloma 89Glioblastoma 77Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Brain Neoplasms 73Head and Neck Neoplasms 72Carcinoma, Hepatocellular 67Squamous Cell Carcinoma of Head and Neck 65Melanoma 62Uterine Cervical Neoplasms 61Ovarian Neoplasms 59Neoplasm Metastasis 55Rectal Neoplasms 52Hematologic Neoplasms 50Recurrence 48Stomach Neoplasms 47Glioma 46Myelodysplastic Syndromes 45Motor Activity 45Triple Negative Breast Neoplasms 44Carcinoma, Renal Cell 44Endometrial Neoplasms 43Sarcoma 41

Interventions

tislelizumab 1epalrestat 1donafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Diabetes Mellitus × 30 days × Clear all
NCT07557914 2026-06-03

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

First Hospital of China Medical University

Phase 2 Not yet recruiting
32 enrolled
Gastrointestinal

Diabetes Mellitus, Carcinoma, Hepatocellular

NCT05124405 2026-05-20

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

M.D. Anderson Cancer Center

Phase NA Active not recruiting
35 enrolled

Diabetes Mellitus, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡